ACLX
Closed
Arcellx Inc
64.69
-1.16 (-1.76%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 65.85
Day's Range: 63.13 - 65.805
Send
sign up or login to leave a comment!
When Written:
30.81
Arcellx Inc is a clinical-stage biotechnology company that develops next-generation engineered cell therapies for patients with cancer and autoimmune diseases. The company's proprietary platform technology, called ARC-SparX, enables the creation of highly specific and potent cell therapies that can be activated and controlled in vivo.
Arcellx's lead product candidate, AX-003, is a CAR-T cell therapy that targets CD19 and CD20, two proteins commonly found on the surface of B-cell malignancies. The company is also developing a pipeline of ARC-SparX cell therapies for the treatment of solid tumors and autoimmune diseases.
Founded in 2015, Arcellx is headquartered in Gaithersburg, Maryland, and has raised over $130 million in funding from investors such as NEA, Novo Holdings, and SR One.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Arcellx's lead product candidate, AX-003, is a CAR-T cell therapy that targets CD19 and CD20, two proteins commonly found on the surface of B-cell malignancies. The company is also developing a pipeline of ARC-SparX cell therapies for the treatment of solid tumors and autoimmune diseases.
Founded in 2015, Arcellx is headquartered in Gaithersburg, Maryland, and has raised over $130 million in funding from investors such as NEA, Novo Holdings, and SR One.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!